Combination of Tocilizumab and Steroids to Improve Mortality in Patients with Severe COVID-19 Infection: A Spanish, Multicenter, Cohort Study

Autor: María J. Pedrosa-Martínez, Paloma Gijón, Víctor Moreno-Torres, Consuelo Pedrós, Ferran Torres, Aránzazu Sancho-López, Ana Fernández-Cruz, Francisco Abad-Santos, Enrique Sánchez-Chica, Itziar de Pablo-López, Paulina García-López, Consuelo Rodríguez-Jiménez, Guillermo Prada-Ramallal, Rocío Sanjuan-Jimenez, Ana Aldea-Perona, Carolina Hernández-Carballo, Belén Ruiz-Antorán, Ruth M. Aparicio-Hernández, Lourdes Cabrera-García, E. Montané, Roser Llop-Rius, Josefa A. Aguilar-García, Clara M. Rosso-Fernández, Evelyn I. Ortiz-Barraza

Publikováno v: Infectious Diseases and Therapy
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
instname

BackgroundWe aimed to determine the impact of tocilizumab use in severe COVID-19 pneumonia mortality.MethodsWe performed a multicentre retrospective cohort study in 18 tertiary hospitals in Spain, from March to April 2020. Consecutive patients admitt

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::72e382b1e688fac9b933f9398cdd99b2
https://pubmed.ncbi.nlm.nih.gov/33280066